Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma.
Adherent peripheral blood mononuclear cell-derived dendritic cells pulsed with autologous idiotypic protein (Id) were given to a patient with advanced-stage refractory myeloma. Potentially beneficial antimyeloma Id-specific immune responses were produced, characterized by MHC-dependent T-cell-proliferative responses with cytokine release and the production of anti-Id antibodies. A T-cell line generated after vaccination was also able to lyse autologous Id-pulsed targets and recognize fresh autologous myeloma cells. The immune responses were associated with a transient minor fall in the serum Id level and were not ablated by high-dose myeloablative chemotherapy. This report therefore demonstrates the clinical use of adherent peripheral blood mononuclear cell-derived dendritic cells for vaccination in cancer and the persistence of immune responses after high-dose chemotherapy. Such a therapeutic approach may be useful in reducing the relapse rate in patients who have minimal residual disease after chemotherapy.
Wen
Y J
YJ
Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, United Kingdom.
Ling
M
M
Bailey-Wood
R
R
Lim
S H
SH
D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D000912:Antibodies, Neoplasm / Q000097:blood; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008297:Male; D008558:Melphalan / Q000494:pharmacology / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology*; D014611:Vaccination
D000888:Antibodies, Anti-Idiotypic; D000912:Antibodies, Neoplasm; D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan